The October issue of Medical Laboratory Observer features an article written by Satabhisa Mukhopadhyay, Ph.D., 4D Path’s founder and Chief Scientific Officer, about advances in computational digital pathology that hold the promise of automating hematoxylin and eosin (H&E) image-based detection and prognostic evaluation of breast cancers. The article examines how “digitally extracted” biomarkers from H&E whole slide images (WSIs) can support prognostication and therapy response prediction, and whether an automated, clinically informed digital pathology workflow could possibly be powered by the development of cell cycle and immune interaction-targeted surrogate biomarkers generated from H&E WSIs – and achieve a viable reimbursement pathway.
